СЕПСИС И ТЕРАГНОСТИКА. НА ПУТИ К ПЕРСОНАЛИЗИРОВАННОЙ МЕДИЦИНЕ
https://doi.org/10.21292/2078-5658-2015-12-6-60-67
Аннотация
Об авторах
В. А. РудновРоссия
доктор медицинских наук, профессор, заведующий кафедрой анестезиологии, реаниматологии и токсикологии
В. В. Кулабухов
Россия
кандидат медицинских наук, заведующий отделением анестезиологии и реанимации
Список литературы
1. Мороз В. В., Смелая Т. В., Голубев А. М. и др. Генетика и медицина критических состояний: от теории к практике // Общ. реаниматол. - 2012. - VIII. - № 4. - С. 4-12.
2. Annane D., Bellissant E., Bollaert P.-E. et al. Corticosteroids in treatment severe sepsis and septic shock in adults. A systematic review // JAMA. - 2009. - Vol. 301, № 22. - P. 2362-2375.
3. Annane D. Corticosteroids for severe sepsis: an evidence-based guide for physicians // Ann. Intens. Care. - 2011. - Vol. 1. - P. 7-13.
4. Bone R. C. Sir Isaac Newton, sepsis, SIRS, and CARS // Crit. Care Med. - 1996. - Vol. 31. - P. 1125-1128.
5. Behnes M., Bertsch T., Lepiorz D. et al. Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment // Crit. Care. - 2014. - Vol. 18. - P. 507.
6. Claus R., Otto, G. P., Deigner H.-P. et al. Approaching clinical reality: markers for monitoring systemic inflammation and sepsis // Curr. Mol. Med. - 2010. - Vol. 10. - P. 227-235.
7. Chrousos G. P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation // N. Engl. J. Med. - 1995. - Vol. 332. - P. 1351-1362.
8. Cruz D., Perazella M., Bellomo R. et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review // Crit. Care.- 2007. - Vol. 11. - Р. R47.
9. Cruz D., Antonelli M., Fumagalli R. et al. Early use of polymyxin B hemoperfusion in abdominal septic shock. The EUPHAS randomized controlled trial // JAMA. - 2009. - Vol. 301. - P. 2445-2452.
10. Croxatto A., Prod’hom G., Greub G. Application of MALDI-TOF MS in clinical diagnostic microbiology // FEMS Microbiol Rev. - 2012. - Vol. 36. - P. 380-407.
11. Dellinger R. P., Levy M., Rhodes A. et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012 // Crit. Care Med. - 2013. - Vol. 41, Suppl. 2. - P. 580-637.
12. Endo S. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study // J. Infect. Chemother. - 2012. - Vol. 18, № 6. - P. 891-897.
13. Gendrel D., Raymond J., Cost J. et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections // Pediatr. Infect. Dis. J. - 1999. - Vol. 18. - P. 875-818.
14. Harbarth S., Holockova K., Froidevaux C. Diagnostic value of procalcitonin, interleukin-6 and interleukin-8 in critically ill patients admitted with suspected sepsis // Am. J. Respir. Crit. Care Med. - 2001. - Vol. 164. - P. 396-402.
15. van Hal S., Lodise T., Paterson D. The clinical significance of vancomycin MIC in S. aureus: systematic review and meta-analysis // CID.- 2012. - Vol. 54. - P. 755-771.
16. Hoffmann J., Wiedermann C., Juers M. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin // Thromb. Haemost. - 2006. - Vol. 95, № 5. - P. 850-856.
17. Kellum J., Kong L., Fink M. et al. Understanding the inflammatory cytokin response in pneumonia and sepsis // Arch. Intern. Med. - 2007. - Vol. 167. - P. 1655-1663.
18. Kotz K., XiaoW., Miller-Graziano C. et al. Inflammation and the host response to injury collaborative research program. Clinical microfluidics for neutrophil genomics and proteomics // Nat. Med. - 2010. - Vol. 16. - P. 1042-1047.
19. Kelkar S. S., Reineke T. M. Theranostics: combining imaging and therapy // Bioconjug Chem. - 2011. - Vol. 22. - P. 1879-1903.
20. Kienast J., Juers M., Wiedermann C. Treatment effects of high dose antithrombin witout concomitant heparin with severe sepsis with or without disseminated intravascular coagulation // J. Thromb. Haemost. - 2006. - Vol. 4. - P. 90-97.
21. Klein D., Derzko A., Foster D. et al. Daily variation in endotoxin levels is associated with increased organ failure in critically ill patients // Shock. - 2007. - Vol. 28. - P. 524-529.
22. Kulabukhov V. Use of an endotoxin adsorber in the treatment of severe abdominal sepsis // Acta Anaesthesiol. Scand. - 2008. - Vol. 52, № 7. - P. 1024-1025.
23. Lichtner R. B. Estrogen/EGF receptor interaction in brest cancer: rational for new therapeutic combination strategies // Biomed. Pharmather. - 2006. - Vol. 57. - P. 447-451.
24. Marshall J. Why have clinical trials in sepsis failed? // Trends. Mol. Med. - 2014. - Vol. 20, № 4. - P. 95-203.
25. Marshall J., Foster D., Vincent J.-L. et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study // J. Infect. Dis. - 2004. - Vol. 190. - P. 527-534.
26. Marik P. Glucocorticoids in sepsis: dissecting facts from fiction // Crit. Care. - 2011. - Vol. 15. - P. 158.
27. Moor C. L., Osaki-Kiyan P., Haque N. et al. Daptomycin vs Vancomycin for bloodstream infections due to methicillin-resistant staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study // CID. - 2012. - Vol. 54. - P. 51-59.
28. Ospina-Tascón G., Büchele G. Vincent J.-L. Multicenter, randomized, controlled trials evaluating mortality in intensive care: Doomed to fail? // Crit. Care Med.- 2008. - Vol. 36. - P. 1311-1322.
29. Pene F., Courtine E., Cariou A. et al. Toward theragnostics // Crit. Care Med. - 2009. - Vol. 37, № 1. - P. 50-58.
30. Prkno A., Waker C., Brunkhorst F. et al. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock - a systematic review and meta-analysis // Crit. Care. - 2013. - Vol. 17. - Р. R291.
31. Romaschin A., Harris D., Ribeiro M. et al. A rapid assay of endotoxin in whole blood using autologous neutrophil-dependent chemiluminescence // J. Immunol. Methods. - 1998. - Vol. 212. - P. 169-185.
32. Robrique L., Sejourne C., Kipnis E. et al. A composite score combining procalcitonin, C-reactive protein and temperature has a high positive value for diagnosis of intensive care-acquired infections // BMC Infect. Dis. - 2013. - Vol. 13. - P. 159.
33. Sligl W., Miner D. A., Sundurr S. et al. Safety and efficacy of corticosteroids forv the treatment of septic shock: systematic review and meta-analysis // CID 2009. - Vol. 49. - P. 93-101.
34. Shedel I., Dreilhausen U., Nentwig B. Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial // Crit. Care Med. - 1991. - Vol. 19. - P. 1104-1113.
35. Shozushima T., Takahashi G., Matsumoto N. et al. Usefulness of presepsin measurement as marker for diagnosis and severity of sepsis that satisfied diagnostic criteria of SIRS // 2011. - Vol. 17, № 6. - P. 764-769.
36. Schmid P., Fischer A., Wuillemin W. Low-molecular wight hparin in patients with renal insufficiency // Swiss Med. Wikly. - 2009. - Vol. 139. - P. 438-452.
37. Tojo M., Fujita T., Ainoda Y. et al. Evaluation of an automated rapid diagnostic assay for detection of gram-negative bacteria and their drug-resistance genes in positive blood cultures // Plos One. - 2014. - Vol. 9.- ID e07315.
38. Ulla M., Pizzolato E., Lucchiari M. et al. Diagnostic and prognostic value of presepsin in the management os sepsis in emergency department: a multicenter prospective study // Crit. Care. - 2013. - Vol. 17. - Р. R168.
39. Vlek A., Bonten M., Boel E. Direct matrix-assisted laser desorption ionization time of flight mass-spectrometry improve appropriateness of antibiotic treatment of bacteremia // Plos One. - 2012. - Vol. 7. - Р. e32589.
40. Warner S. Diagnostic + Therapy = Theragnostic // Scientist. - 2004. - Vol. 18. - P. 38-39.
41. Wacker C., Prkno A., Brunkhorst P. et al. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis // Lancet Inf. Dis. - 2013. - Vol. 13. - P. 426-435.
42. Warren B., Eid A., Singer P. et al. High-dose antithrombine III in severe sepsis. A randomized controlled trial // JAMA. - 2001. - Vol. 286. - P. 1869-1878.
43. Winning J., Claus R., Huse R. et al. Molecular biology on ICU // Minerva anestesiol. - 2006. - Vol. 72. - P. 255-267.
44. Wong H., Cvijanovich N., Allen G. et al. Validation of a gene expression-based subclassification strategy for pediatric septic shock // Crit. Care Med. - 2009. - Vol. 39. - P. 2511-2517.
45. Wong H., Cvijanovich N., Anas N. et al. Developing a clinical feasible personalized medicine approach to pediatric septic shock // Am. J. Res. Crit. Care Med. - 2015. - Vol. 191. - P. 309-315.
Рецензия
Для цитирования:
Руднов В.А., Кулабухов В.В. СЕПСИС И ТЕРАГНОСТИКА. НА ПУТИ К ПЕРСОНАЛИЗИРОВАННОЙ МЕДИЦИНЕ. Вестник анестезиологии и реаниматологии. 2015;12(6):60-67. https://doi.org/10.21292/2078-5658-2015-12-6-60-67
For citation:
Rudnov V.A., Kulabukhov V.V. SEPSIS AND TERAGNOSTICS. ON THE WAY TO PERSONIFIED MEDICINE. Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2015;12(6):60-67. (In Russ.) https://doi.org/10.21292/2078-5658-2015-12-6-60-67